[Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)]

[Article in German]

[Article in German]

Hans-Konrad Selbmann. MMW Fortschr Med. 2009.

. 2009 Aug 20;151(34-35):6.

No abstract available

Similar articles

["There are clear criteria for product surveillance studies"].
Throm S. Throm S. MMW Fortschr Med. 2009 Aug 20;151(34-35):7. MMW Fortschr Med. 2009. PMID: 19771777 German. No abstract available.
Post-marketing surveillance of drugs.
Bell KD. Bell KD. Med J Aust. 1991 Apr 15;154(8):567. Med J Aust. 1991. PMID: 2064665 No abstract available.
[Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
Gleiter CH, Bieck PR. Gleiter CH, et al. Fortschr Med. 1991 Jul 20;109(21):429-31. Fortschr Med. 1991. PMID: 1916572 German. No abstract available.
Decision support methods for the detection of adverse events in post-marketing data.
Hauben M, Bate A. Hauben M, et al. Drug Discov Today. 2009 Apr;14(7-8):343-57. doi: 10.1016/j.drudis.2008.12.012. Epub 2009 Jan 31. Drug Discov Today. 2009. PMID: 19187799 Review.
[Postmarketing surveillance studies in community pharmacies].
Nieber K, Lehmacher W. Nieber K, et al. Med Monatsschr Pharm. 2009 Aug;32(8):301-6. Med Monatsschr Pharm. 2009. PMID: 19777737 Review. German.